|
WO2018119033A1
|
|
Abuse-resistant and abuse-deterrent dosage forms
|
|
WO2018044895A1
|
|
Immediate release dosage forms with abuse deterrence and alcohol resistance
|
|
WO2018013771A1
|
|
Treatment of pain using hydrocodone formulations
|
|
US2017157052A1
|
|
Immediate release dosage forms that deter abuse by oral ingestion of multiple dosage units
|
|
CA2970065A1
|
|
Immediate release abuse-deterrent granulated dosage forms
|
|
WO2015066172A1
|
|
Immediate release abuse-deterrent granulated dosage forms
|
|
US2015118300A1
|
|
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
|
WO2015065546A2
|
|
Abuse-deterrent dosage forms
|
|
US2013122101A1
|
|
Abuse resistant drug formulation
|
|
CA2798702A1
|
|
Alcoholresistant metoprolol-containing extended-release oral dosage forms
|
|
EP2579857A1
|
|
Alcohol-resistant extended release dosage forms comprising venlafaxine
|
|
NZ603531A
|
|
Alcohol-resistant formulations
|
|
CN102770127A
|
|
Abuse-resistant formulations
|
|
MX2012006829A
|
|
Abuse-resistant formulations.
|
|
MX2010002780A
|
|
Abuse resistant drug formulation.
|
|
MX2009005671A
|
|
Oral transmucosal nicotine dosage form.
|
|
CN101563071A
|
|
Oral transmucosal nicotine dosage form
|
|
US2008069891A1
|
|
Abuse resistant drug formulation
|
|
US2008031944A1
|
|
Stabilization of lorazepam
|
|
US2008031949A1
|
|
High dose orally dissolvable/disintegrable lyophilized dosage form
|
